Pyxis Oncology Stock Today
| PYXS Stock | USD 2.01 0.18 9.84% |
Performance0 of 100
| Odds Of DistressLess than 49
|
Pyxis Oncology is selling for under 2.01 as of the 30th of November 2024; that is 9.84 percent increase since the beginning of the trading day. The stock's lowest day price was 1.97. Pyxis Oncology has 49 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Pyxis Oncology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of January 20222022 | Category Healthcare | Classification Health Care |
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 59.47 M outstanding shares of which 5.84 M shares are at this time shorted by private and institutional investors with about 8.24 trading days to cover. More on Pyxis Oncology
Moving against Pyxis Stock
| 0.34 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
Pyxis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | MBA MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPyxis Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pyxis Oncology's financial leverage. It provides some insight into what part of Pyxis Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Pyxis Oncology (PYXS) is traded on NASDAQ Exchange in USA. It is located in 321 Harrison Avenue, Boston, MA, United States, 02118 and employs 54 people. Pyxis Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 119.53 M. Pyxis Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.47 M outstanding shares of which 5.84 M shares are at this time shorted by private and institutional investors with about 8.24 trading days to cover.
Pyxis Oncology currently holds about 223.36 M in cash with (70.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pyxis Oncology Probability Of Bankruptcy
Ownership AllocationPyxis Oncology owns a total of 59.47 Million outstanding shares. Over half of Pyxis Oncology's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pyxis Ownership Details
Pyxis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Perceptive Advisors Llc | 2024-09-30 | 508.5 K | |
| 683 Capital Management Llc | 2024-09-30 | 414.7 K | |
| Northern Trust Corp | 2024-09-30 | 394 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 382.8 K | |
| Hillhouse Capital Advisors, Ltd. | 2024-09-30 | 382.6 K | |
| Decheng Capital Llc | 2024-06-30 | 326.8 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 311.6 K | |
| Boothbay Fund Management, Llc | 2024-09-30 | 283.6 K | |
| Citadel Advisors Llc | 2024-09-30 | 276 K | |
| Deep Track Capital, Lp | 2024-09-30 | 4.2 M | |
| Laurion Capital Management Lp | 2024-09-30 | 3.6 M |
Pyxis Oncology Historical Income Statement
Pyxis Stock Against Markets
Pyxis Oncology Corporate Management
| Balu Balasubramanian | Interim Officer | Profile | |
| Jan Pinkas | Chief Officer | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Charles Gombar | Senior Management | Profile | |
| MBA MBA | CoFounder Chairman | Profile | |
| MD FACP | Chief Officer | Profile | |
| Jitendra Wadhane | Senior Officer | Profile |
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.